联合治疗-话题@MedSci

#联合治疗#

277篇内容 | 4249人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1313721, encodeId=a6691313e214f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NEJM：三药联合治疗淋巴丝虫病的疗效分析, objectType=article, longId=153051, objectId=894215305189, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=894215305189, replyNumber=0, likeNumber=62, createdTime=2018-11-10, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=894215305189, moduleTitle=NEJM：三药联合治疗淋巴丝虫病的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=894215305189)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313720, encodeId=f5bc1313e2042, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Biomed Pharmacother：肉桂醛和β-TCP联合治疗对卵巢切除大鼠临界尺寸颅骨缺损的骨形成和血管生成具有累加作用, objectType=article, longId=153013, objectId=157015301309, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=157015301309, replyNumber=0, likeNumber=68, createdTime=2018-11-09, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=157015301309, moduleTitle=Biomed Pharmacother：肉桂醛和β-TCP联合治疗对卵巢切除大鼠临界尺寸颅骨缺损的骨形成和血管生成具有累加作用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=157015301309)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313719, encodeId=62991313e1992, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=JCO：氟嘧啶，伊立替康和贝伐单抗联合治疗转移性结直肠癌：一项随机对照研究, objectType=article, longId=152750, objectId=242a152e506d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=242a152e506d, replyNumber=0, likeNumber=72, createdTime=2018-11-05, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=242a152e506d, moduleTitle=JCO：氟嘧啶，伊立替康和贝伐单抗联合治疗转移性结直肠癌：一项随机对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=242a152e506d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313718, encodeId=e83e1313e18b9, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=FDA延长了对Opdivo/Yervoy联合治疗方案的审查, objectType=article, longId=151495, objectId=41d015149554, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41d015149554, replyNumber=0, likeNumber=55, createdTime=2018-10-23, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41d015149554, moduleTitle=FDA延长了对Opdivo/Yervoy联合治疗方案的审查, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41d015149554)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313717, encodeId=1c9a1313e17fa, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Endocrine：PTH1-34加MK-4联合治疗可在骨质减少的情况下加速颅骨骨缺损中的骨形成和血管生成, objectType=article, longId=150948, objectId=87fa15094818, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=87fa15094818, replyNumber=0, likeNumber=54, createdTime=2018-10-15, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=87fa15094818, moduleTitle=Endocrine：PTH1-34加MK-4联合治疗可在骨质减少的情况下加速颅骨骨缺损中的骨形成和血管生成, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=87fa15094818)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313716, encodeId=ad561313e1693, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Cell Biochem：拉帕替尼和紫杉醇的单独或联合治疗会导致骨质流失和骨髓脂肪化, objectType=article, longId=150629, objectId=63851506291d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=63851506291d, replyNumber=0, likeNumber=53, createdTime=2018-10-10, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=63851506291d, moduleTitle=J Cell Biochem：拉帕替尼和紫杉醇的单独或联合治疗会导致骨质流失和骨髓脂肪化, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=63851506291d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313715, encodeId=615d1313e150b, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=NATURE：HIV-1抗体的联合治疗维持病毒长期抑制, objectType=article, longId=149986, objectId=138f14998695, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=138f14998695, replyNumber=0, likeNumber=58, createdTime=2018-09-30, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=138f14998695, moduleTitle=NATURE：HIV-1抗体的联合治疗维持病毒长期抑制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=138f14998695)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313714, encodeId=04be1313e14f7, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, objectType=article, longId=149701, objectId=7340149e01c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7340149e01c4, replyNumber=0, likeNumber=70, createdTime=2018-09-28, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7340149e01c4, moduleTitle=AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7340149e01c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313713, encodeId=e05f1313e1307, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Daiichi宣布开展临床试验：评价其在研抗体偶联药物和Keytruda联合治疗乳腺癌和肺癌的药效, objectType=article, longId=149488, objectId=4ea8149488e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ea8149488e4, replyNumber=0, likeNumber=64, createdTime=2018-09-25, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ea8149488e4, moduleTitle=Daiichi宣布开展临床试验：评价其在研抗体偶联药物和Keytruda联合治疗乳腺癌和肺癌的药效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4ea8149488e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313712, encodeId=cd111313e1218, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Keytruda/Alimta联合治疗NSCLC获美国FDA批准, objectType=article, longId=147278, objectId=cb7e14e27873, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cb7e14e27873, replyNumber=0, likeNumber=68, createdTime=2018-08-24, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cb7e14e27873, moduleTitle=Keytruda/Alimta联合治疗NSCLC获美国FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cb7e14e27873)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313711, encodeId=8eb81313e110f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症, objectType=article, longId=146626, objectId=e59d146626ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e59d146626ef, replyNumber=0, likeNumber=62, createdTime=2018-08-16, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e59d146626ef, moduleTitle=Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e59d146626ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313710, encodeId=dfb61313e10c2, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Eur Respir J：尼达尼布与吡非尼酮联合治疗特发性肺纤维化的安全性分析, objectType=article, longId=145895, objectId=06b8145895d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06b8145895d8, replyNumber=0, likeNumber=84, createdTime=2018-08-06, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06b8145895d8, moduleTitle=Eur Respir J：尼达尼布与吡非尼酮联合治疗特发性肺纤维化的安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06b8145895d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313709, encodeId=ff971313e0969, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=PLoS Med：老年高血压患者：FDC治疗vs多丸联合治疗, objectType=article, longId=145813, objectId=5490145813c5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5490145813c5, replyNumber=0, likeNumber=74, createdTime=2018-08-05, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5490145813c5, moduleTitle=PLoS Med：老年高血压患者：FDC治疗vs多丸联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5490145813c5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313708, encodeId=b6d41313e08e5, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Liver Int：：DAA联合治疗肝移植后的丙肝复发是非常有效和耐受的, objectType=article, longId=145290, objectId=b1b614529070, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b1b614529070, replyNumber=0, likeNumber=66, createdTime=2018-07-28, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b1b614529070, moduleTitle=Liver Int：：DAA联合治疗肝移植后的丙肝复发是非常有效和耐受的, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b1b614529070)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313707, encodeId=291e1313e0797, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Circulation：他汀和PCSK9联合治疗的患者的残余炎症风险, objectType=article, longId=144130, objectId=d8d4144130c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d8d4144130c0, replyNumber=0, likeNumber=87, createdTime=2018-07-13, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d8d4144130c0, moduleTitle=Circulation：他汀和PCSK9联合治疗的患者的残余炎症风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d8d4144130c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313706, encodeId=bcc01313e0688, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=Chest：肺动脉高压联合治疗试验长时间随访是在做无用功？, objectType=article, longId=141177, objectId=9a711411e7f1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9a711411e7f1, replyNumber=0, likeNumber=98, createdTime=2018-06-22, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9a711411e7f1, moduleTitle=Chest：肺动脉高压联合治疗试验长时间随访是在做无用功？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9a711411e7f1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313705, encodeId=039e1313e0534, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=【2018EHA抢先看】一种新方法：或有助于优化CLL伊布替尼联合治疗策略, objectType=article, longId=139495, objectId=8d8c13949555, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d8c13949555, replyNumber=0, likeNumber=61, createdTime=2018-06-01, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d8c13949555, moduleTitle=【2018EHA抢先看】一种新方法：或有助于优化CLL伊布替尼联合治疗策略, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8d8c13949555)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313704, encodeId=be001313e043f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=PLoS One：电刺激和胰岛素样生长因子-1联合治疗可更有效的促进骨再生, objectType=article, longId=138602, objectId=7d8a138602b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7d8a138602b6, replyNumber=0, likeNumber=61, createdTime=2018-05-21, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7d8a138602b6, moduleTitle=PLoS One：电刺激和胰岛素样生长因子-1联合治疗可更有效的促进骨再生, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7d8a138602b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313703, encodeId=cb2c1313e033c, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=【2018 ASCO】免疫联合治疗NSCLC鳞癌再赢一局！KEYNOTE-407研究精彩抢先看, objectType=article, longId=138592, objectId=6ffc1385926a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ffc1385926a, replyNumber=0, likeNumber=101, createdTime=2018-05-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ffc1385926a, moduleTitle=【2018 ASCO】免疫联合治疗NSCLC鳞癌再赢一局！KEYNOTE-407研究精彩抢先看, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6ffc1385926a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1313702, encodeId=ad571313e021f, content=<a href='/topic/show?id=d4cc80e128f' target=_blank style='color:#2F92EE;'>#联合治疗#</a>, objectTitle=J Infect：肺炎链球菌肺炎：第三代头孢菌素单一治疗vs联合治疗, objectType=article, longId=138507, objectId=6eda13850e9d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6eda13850e9d, replyNumber=0, likeNumber=82, createdTime=2018-05-20, rootId=0, userName=zhaozuguo, userId=263b421, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6eda13850e9d, moduleTitle=J Infect：肺炎链球菌肺炎：第三代头孢菌素单一治疗vs联合治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6eda13850e9d)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

联合治疗

2020-05-29

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NEJM：三药联合治疗淋巴丝虫病的疗效分析

2018-11-10

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Biomed Pharmacother：肉桂醛和β-TCP联合治疗对卵巢切除大鼠临界尺寸颅骨缺损的骨形成和血管生成具有累加作用

2018-11-09

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

JCO：氟嘧啶，伊立替康和贝伐单抗联合治疗转移性结直肠癌：一项随机对照研究

2018-11-05

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

FDA延长了对Opdivo/Yervoy联合治疗方案的审查

2018-10-23

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Endocrine：PTH1-34加MK-4联合治疗可在骨质减少的情况下加速颅骨骨缺损中的骨形成和血管生成

2018-10-15

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Cell Biochem：拉帕替尼和紫杉醇的单独或联合治疗会导致骨质流失和骨髓脂肪化

2018-10-10

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

NATURE：HIV-1抗体的联合治疗维持病毒长期抑制

2018-09-30

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

AbbVie的BCL-2抑制剂VENCLEXTA获得加拿大批准与利妥昔单抗联合治疗慢性淋巴细胞白血病患者

2018-09-28

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Daiichi宣布开展临床试验：评价其在研抗体偶联药物和Keytruda联合治疗乳腺癌和肺癌的药效

2018-09-25

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Keytruda/Alimta联合治疗NSCLC获美国FDA批准

2018-08-24

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Unum Therapeutics宣布研究性新药（IND）申请：抗体偶联T细胞受体（ACTR）细胞疗法和曲妥珠单抗联合治疗HER2阳性晚期癌症

2018-08-16

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Eur Respir J：尼达尼布与吡非尼酮联合治疗特发性肺纤维化的安全性分析

2018-08-06

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

PLoS Med：老年高血压患者：FDC治疗vs多丸联合治疗

2018-08-05

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Liver Int：：DAA联合治疗肝移植后的丙肝复发是非常有效和耐受的

2018-07-28

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Circulation：他汀和PCSK9联合治疗的患者的残余炎症风险

2018-07-13

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

Chest：肺动脉高压联合治疗试验长时间随访是在做无用功？

2018-06-22

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

【2018EHA抢先看】一种新方法：或有助于优化CLL伊布替尼联合治疗策略

2018-06-01

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

PLoS One：电刺激和胰岛素样生长因子-1联合治疗可更有效的促进骨再生

2018-05-21

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

【2018 ASCO】免疫联合治疗NSCLC鳞癌再赢一局！KEYNOTE-407研究精彩抢先看

2018-05-20

zhaozuguo (审核中...)

前往app查看评论内容

#联合治疗#

J Infect：肺炎链球菌肺炎：第三代头孢菌素单一治疗vs联合治疗

2018-05-20

科室
- - 订阅+
  - 更多科室
工具
服务